Takeda Highlights Rare Neurological Disorder Programs In Wave 1

Company Already Has Pivoted Away From Larger Psychiatric Indications

 
• By Joseph Haas
Takeda Tokyo HQ
Takeda gave investors another update on its Wave 1 R&D effort

More from Neurological

More from Therapeutic Category